

An Indications, Off-Label Uses, Mechanism of Action, Pharmacokinetics, Administration, Adverse Effects, Contra Indications of Niacin B3
Abstract
Niacin, also known as vitamin B3, belongs to the water-soluble B complex group and is observed in various foods namely bran, yeast, eggs, peanuts, poultry, red meat, fish, whole-grain cereals, legumes, and seeds. This essential vitamin plays a role in cellular metabolism as a vital component especially in the oxidized state of nicotinamide adenine dinucleotide (NAD, or coenzyme 1) and the reduced form of nicotinamide adenine dinucleotide phosphate (NADP, or coenzyme 2). These coenzymes are involved in an active manner particularly in essential oxidation-reduction reactions, playing key roles in glycolysis, pyruvate metabolism, protein and amino acid metabolism, pentose biosynthesis, glycerol metabolism, synthesis of high-energy phosphate bonds, and fatty acid metabolism. Niacin assists regarding management of hyperlipidemia and is used off-label in treating pellagra, as an adjuvant particularly for discoid lupus erythematosus, and for reducing dermatological and neurological symptoms linked to NAXD and NAXE deficiencies. This activity explains about the mechanism of action, indications, dosing, administration, and contraindications of niacin.
References
Pownall, H. J., Jackson, R. L., Roth, R. I., Gotto, A. M., Patsch, J. R., & Kummerow, F. A. (1980). Influence of an atherogenic diet on the structure of swine low density lipoproteins. Journal of Lipid Research, 21(8), 1108-1115.
Hegyi, J., Schwartz, R. A., & Hegyi, V. (2004). Pellagra: Dermatitis, dementia, and diarrhea. International Journal of Dermatology, 43(1), 1-5.
Wilson, P. W. F., Polonsky, T. S., Miedema, M. D., Khera, A., Kosinski, A. S., & Kuvin, J. T. (2019). Systematic review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 139(25), e1144-e1161.
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., ... & Yeboah, J. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 139(25), e1082-e1143.
Handelsman, Y., Jellinger, P. S., Guerin, C. K., Bloomgarden, Z. T., Brinton, E. A., Budoff, M. J., ... & Wyne, K. L. (2020). Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm—2020 executive summary. Endocrine Practice, 26(10), 1196-1224.
Rubin de Celis Ferrari, A. C., Glasberg, J., & Riechelmann, R. P. (2018). Carcinoid syndrome: Update on the pathophysiology and treatment. Clinics (São Paulo), 73(suppl 1), e490s.
Wang, X., Li, X. Y., Piao, Y., Yuan, G., Lin, Y., Chen, H., ... & Wang, C. (2022). Hartnup disease presenting as hereditary spastic paraplegia and severe peripheral neuropathy. American Journal of Medical Genetics Part A, 188(1), 237-242.
Narasimha, V. L., Ganesh, S., Reddy, S., Shukla, L., Mukherjee, D., Kandasamy, A., ... & Murthy, P. (2019). Pellagra and alcohol dependence syndrome: Findings from a tertiary care addiction treatment centre in India. Alcohol and Alcoholism, 54(2), 148-151.
Van Bergen, N. J., Walvekar, A. S., Patraskaki, M., Sikora, T., Linster, C. L., & Christodoulou, J. (2022). Clinical and biochemical distinctions for a metabolite repair disorder caused by NAXD or NAXE deficiency. Journal of Inherited Metabolic Disease, 45(6), 1028-1038.
Nouh, A. H., Elshahid, A. R., Kadah, A. S., & Zeyada, Y. A. (2023). Topical niacinamide (nicotinamide) treatment for discoid lupus erythematosus (DLE): A prospective pilot study. Journal of Cosmetic Dermatology, 22(5), 1647-1657.
Isaac, S. (1998). The "gauntlet" of pellagra. International Journal of Dermatology, 37(8), 599.
Kashyap, M. L. (1998). Mechanistic studies of high-density lipoproteins. American Journal of Cardiology, 82(12A), 42U-48U; discussion 85U-86U.
Zeman, M., Vecka, M., Perlík, F., Hromádka, R., Staňková, B., Tvrzická, E., & Žák, A. (2015). Niacin in the treatment of hyperlipidemias in light of new clinical trials: Has niacin lost its place? Medical Science Monitor, 21, 2156-2162.
Gasperi, V., Sibilano, M., Savini, I., & Catani, M. V. (2019). Niacin in the central nervous system: An update of biological aspects and clinical applications. International Journal of Molecular Sciences, 20(4), 895.
Schandelmaier, S., Briel, M., Saccilotto, R., Olu, K. K., Arpagaus, A., Hemkens, L. G., & Nordmann, A. J. (2017). Niacin for primary and secondary prevention of cardiovascular events. Cochrane Database of Systematic Reviews, 6, CD009744.
Refbacks
- There are currently no refbacks.